Director
Gilead Sciences, Inc
Foster City, California, United States
Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
92 - Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial
Thursday, October 17, 2024
11:30 AM – 11:43 AM US PT